Lilly Should Survive Patent Loss on Blockbuster Drug Zyprexa

However, investors might have to stick through a couple lean years

Ten years ago, some industry observers wondered if Eli Lilly (NYSE:LLY) could survive as an independent company when it lost patent protection on Prozac. At the time, they pointed to the fact that the anti-depressant accounted for more than one-third of company sales.

But the Indianapolis-based pharma giant survived that blow and avoided being driven into the arms of a waiting suitor. The question today is: Can Lilly do it again?